Abstract
Proteinase-activated Receptor 2 (PAR2) is a potential target for the design of drug treatments for vascular diseases. Its unique mechanism of activation by serine proteinases, questions regarding the identities of endogenous agonists and its apparent multiple activities in the vasculature contribute to complex pharmacology. The progress of the pursuit to understand the function of PAR2 relies on the design of short specific peptides as selective agonists for PAR2 in receptor-selective cultured cell expression systems and is limited by the lack of any PAR2 antagonists. Fortunately, the utilization of transgenic PAR2-deficient mice enables the identification of the actions of selective PAR2-derived activating peptides attributed to activation solely of PAR2 in more physiologically complex systems. Of multiple pharmacological responses, PAR2-derived peptide agonists reduce vascular tone, and therefore increase blood flow, via nitric oxide-dependent and -independent paracrine actions of the endothelium upon the underlying vascular smooth muscle cells of blood vessels. PAR2-mediated endothelial-dependent relaxation and hyperpolarization of vascular smooth muscle in select arterial vascular beds via a nitric oxide / cyclooxygenases-independent mechanism suggests a strategy for correction of endothelium-based vascular dysfunction. Vascular tissues respond to progression of vascular diseases such as atherosclerosis or to injury with variable changes of PAR2 expression. With further research and drug development, PAR2 agonists and antagonists may become a basis for a new class of therapeutic agents for treatment of vascular diseases.
Keywords: par-2, par2, proteinase-activated receptor 2, protease-activated receptor 2, endothelium, nitric oxide, hyperpolarization, vascular smooth muscle, atherosclerosis, hypertension
Current Pharmaceutical Design
Title: Proteinase-Activated Receptor 2 (PAR2): A Challenging New Target for Treatment of Vascular Diseases
Volume: 10 Issue: 22
Author(s): John J. McGuire
Affiliation:
Keywords: par-2, par2, proteinase-activated receptor 2, protease-activated receptor 2, endothelium, nitric oxide, hyperpolarization, vascular smooth muscle, atherosclerosis, hypertension
Abstract: Proteinase-activated Receptor 2 (PAR2) is a potential target for the design of drug treatments for vascular diseases. Its unique mechanism of activation by serine proteinases, questions regarding the identities of endogenous agonists and its apparent multiple activities in the vasculature contribute to complex pharmacology. The progress of the pursuit to understand the function of PAR2 relies on the design of short specific peptides as selective agonists for PAR2 in receptor-selective cultured cell expression systems and is limited by the lack of any PAR2 antagonists. Fortunately, the utilization of transgenic PAR2-deficient mice enables the identification of the actions of selective PAR2-derived activating peptides attributed to activation solely of PAR2 in more physiologically complex systems. Of multiple pharmacological responses, PAR2-derived peptide agonists reduce vascular tone, and therefore increase blood flow, via nitric oxide-dependent and -independent paracrine actions of the endothelium upon the underlying vascular smooth muscle cells of blood vessels. PAR2-mediated endothelial-dependent relaxation and hyperpolarization of vascular smooth muscle in select arterial vascular beds via a nitric oxide / cyclooxygenases-independent mechanism suggests a strategy for correction of endothelium-based vascular dysfunction. Vascular tissues respond to progression of vascular diseases such as atherosclerosis or to injury with variable changes of PAR2 expression. With further research and drug development, PAR2 agonists and antagonists may become a basis for a new class of therapeutic agents for treatment of vascular diseases.
Export Options
About this article
Cite this article as:
McGuire J. John, Proteinase-Activated Receptor 2 (PAR2): A Challenging New Target for Treatment of Vascular Diseases, Current Pharmaceutical Design 2004; 10 (22) . https://dx.doi.org/10.2174/1381612043383656
DOI https://dx.doi.org/10.2174/1381612043383656 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Monitoring Therapeutic Anticoagulation with Low Molecular Weight Heparins: Is it Useful or Misleading?
Cardiovascular & Hematological Agents in Medicinal Chemistry Pattern of Primary Vasculitis with Peripheral Ischemic Manifestations: Report of a Case Series and Role of Vascular Surgery
Current Rheumatology Reviews Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine ACE Inhibition, p300, Serum Nitrite and Lipid Peroxidation in Newly Diagnosed Hypertensives
Vascular Disease Prevention (Discontinued) Obstructive Sleep Apnea Syndrome: Implications in Cardiovascular Disease
Current Respiratory Medicine Reviews The Role of Viruses in Neurodegenerative and Neurobehavioral Diseases
CNS & Neurological Disorders - Drug Targets Chronic Kidney Disease and Thrombosis
Current Pediatric Reviews Onconeural Versus Paraneoplastic Antigens?
Current Medicinal Chemistry Therapy Related Markers and Response Prediction Towards Multimodal Treatment of Carcinomas of the Upper Gastrointestinal Tract
Current Pharmacogenomics and Personalized Medicine Vitamin D Supplementation and Cancer: Review of Randomized Controlled Trials
Anti-Cancer Agents in Medicinal Chemistry To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Development of Physical Disability in Older Adults
Current Aging Science Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Cardiovascular Risk Factors in Chronic Inflammatory Rheumatic Diseases: Modern Assessment and Diagnosis
Current Vascular Pharmacology Past, Present and Future of Electroanalytical Sensor for Aspirin, Ibuprofen and Paracetamol Detection
Current Pharmaceutical Analysis Antenatal Glucocorticoids Supplementation and Central Nervous System Development
Current Drug Metabolism The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders:A Potential Noveltreatment?
Current Neuropharmacology Electrochemical-Based Biosensors: New Diagnosis Platforms for Cardiovascular Disease
Current Medicinal Chemistry Dyslipidaemia Related to Insulin Resistance and Cardiovascular Disease in South Asian and West African Populations
Current Pharmaceutical Design Effects of Endothelins on Cardiac and Vascular Cells: New Therapeutic Target for the Future?
Current Vascular Pharmacology